During the clinical trials for donanemab, there were reports of deaths among participants. Specifically, at least three participants in the donanemab trials died, with their deaths potentially linked to amyloid-related imaging abnormalities (ARIA), a known side effect of amyloid-targeting therapies. These incidents have raised concerns about the safety of the drug and have contributed to the FDA’s cautious approach towards its approval.